Claremont Global Fund
(Hedged)
Own the world's best businesses

Q2 2026 Report
CGHE:ASX

Investment results to 30 June 2026

	Since Inception p.a.	10 years p.a.	7 years p.a.	5 Years p.a.	3 years p.a.	1 year	6 months	3 months	1 month
Claremont Global Fund (Hedged) Active ETF	8.3%	7.7%	5.1%	0.1%	-1.0%	-12.9%	-10.1%	0.6%	-2.0%
MSCI ACWI ex-Australia (Net, Hedged to A$)[1]	11.2%	12.5%	12.6%	10.9%	19.3%	25.4%	11.9%	15.1%	0.0%
Excess Return	-2.9%	-4.8%	-7.5%	-10.8%	-20.3%	-38.3%	-22.0%	-14.5%	-2.1%

[1] Benchmark is MSCI All Countries World Index Ex-Australia (Net, hedged to A$). Performance is net of management fees. Inception: 18th Feb 2014. Figures may not sum due to rounding. Returns assume reinvestment of distributions and are annualised for periods greater than 1 year. Past performance is not indicative of future results.

About Claremont Global

- Claremont Global is a single strategy international equity boutique that has been deliberately structured to invest differently from peers.
- We own a concentrated portfolio of no more than fifteen resilient businesses that grow organically, have high margins and low levels of debt.
- Our investment approach is conservative but not conventional. We exclude large parts of the market that are commoditised, leveraged, complex and cyclical. Valuation matters; our return objective is 8-12% p.a. over the medium to long term.

CY return vs benchmark



Data as of 30 June 2026. Benchmark is MSCI ACWI ex-Australia (Net, hedged to A$). Performance is net of management fees and inclusive of distributions. Past performance is not indicative of future results.

Portfolio exposure by source of revenue



Source: Company Filings, Claremont Global.

Sector weighting



Source: Claremont Global Analysis.

Portfolio quality

Metric	Claremont Global	S&P 500 (Ex-Financials)
Gross margin[1]	54%	35%
EBIT margin[2]	31%	13%
Net debt / EBITDA[3]	1.0x	1.6x
ROIC[4]	17%	11%

Top five holdings[5]

Company	Sector
Agilent	Healthcare
amazon	Information Technology
novonesis	Industrial
VISA	Financial Services
Waste Connections	Industrial

For fund investor use only. Data as of 30 June 2026 unless noted. Views reflect broader portfolio strategy and are not standalone advice. Figures in AUD. Performance data sourced from the Investment Manager. Past performance is not indicative of future results. 1. Weighted average gross margin over trailing five years for current portfolio holdings. 2. Weighted average EBIT margin over the past five financial years for current portfolio. 3. Weighted average Net debt / EBITDA over trailing 12 months for current portfolio holdings. 4. Weighted average ROIC over trailing five years for current portfolio holdings. 5. Top five holdings A-Z.

Portfolio commentary

The Claremont Global Fund's (Fund) performance was slightly positive for the quarter, however it underperformed its benchmark by 14.5%. This was not a quarter where we saw poor fundamental performance across the portfolio companies. In fact, revenue growth and EPS growth averaged 11%. But statistically this was an extraordinary quarter, driven by concentrated momentum, notably within the semiconductor sector which was a large contributor to the benchmark's quarterly performance (as previously discussed, semis/memory chips is an area where the Fund has not historically had exposure, due to its highly cyclical nature).

As portfolio managers we continue to believe in the long-term investment philosophy, approach and positioning of the Fund. The portfolio continues to be conservatively positioned in high quality, attractively valued companies. In the second quarter this style was certainly out of favour. However, we believe it will serve Fund investors well over the long-term, with an attractive risk/reward opportunity in front of us today.

The Fund's holdings are currently trading at an estimated weighted price-to-value of 75% and 22x next-twelve-month earnings. As such, we remain confident of achieving our targeted return of 8-12% p.a. over the medium term.

Key contributors to performance for the quarter were **Agilent** and **Amazon** :

- **Agilent (A-US)** – Reported a strong set of results, above market expectations, with organic revenue growth over 6%. Instruments, innovation, and pricing were key drivers of the result, and the book to bill ratio remained above one for the ninth consecutive quarter, highlighting the ongoing strength in the replacement upcycle. These results were a timely reminder of the ongoing tailwinds from which Agilent is continuing to benefit.
- **Amazon (AMZN-US)** – the company delivered its first quarter result including 15% constant-currency revenue growth and 30% operating income growth. Operating margins were a record at more than 13% this quarter. Of note, AWS revenue growth accelerated to 28% in the quarter (compared to 17% in 1Q25). AWS's run-rate revenue is US$150bn p.a. (AI comprises 10%) and the backlog at the end of 1Q26 is over US$360bn (before taking into account the recent Anthropic deal for US$100bn).

Key detractors to performance for the quarter were **CME Group** and **Zoetis**:

- **CME Group (CME-US)** – following last quarter, when CME was one of the strongest share price performers, the June quarter saw the share price retreat. This was despite reporting record volumes, 14% revenue growth, an adjusted operating margin just below 73%, and 20% adjusted EPS growth for the first quarter.

  Several issues appeared to weigh on the shares during the quarter: a) Concerns about competition following the approval of Bitcoin perpetual futures by the CFTC; b) Hopes for a resolution to key geopolitical issues and the prospect of lower volatility/trading and potentially; c) The well signalled transition of the CEO role from Terry Duffy (who will remain as Executive Chair) to Lynne Fitzpatrick (current CFO). While we continue to monitor developments in the perpetual market we think fears were initially overstated. Further, we view Lynne Fitzpatrick as a capable, well regarded, "safe pair of hands".
- **Zoetis (ZTS-US)** – Following a prior reduction in our Zoetis exposure, we exited the remaining position (c.3%) after the company missed earnings and reduced their organic revenue guide for the year, to 2 - 5%. Management cited weakness in the companion animal segment, and pointed to a stressed US consumer, lower vet visits, channel destocking and increased competitor promotional activity.

Investment results since inception

Growth of AUD $10,000



Benchmark: MSCI ACWI ex-Australia (Net, hedged to A$). Performance is net of investment management fees and inclusive of distributions. Past performance is not indicative of future results.

The company has launched a cost-cutting program to drive earnings, which in our experience suggests there is a reasonable probability of further reduced revenue guidance to come, and a source of lower quality earnings. A key part of our investment thesis was the pricing power and resilient revenue profile of animal healthcare, which has proven less robust than expected. As such, we have taken the capital and re-allocated it to a business where we have higher confidence in the consumer's purchasing power and the company's pricing power.

models, as AI tools become a larger proportion of their service offering and finally, increased discussion of M&A to bolster their position in AI. As a result of these factors, we exited the position.

Portfolio additions

Ferrari (RACE-IM) – Founded in 1939 by Enzo Ferrari, the company has evolved into one of the most coveted brands in the world and has built its heritage on the back of its strong presence in racing. The business generates nearly all its revenue from the sale of sports cars, with some ancillary revenue streams from commercial agreements (Formula 1), sponsorship, fashion and memorabilia, financial services and its racetrack (Mugello circuit).

The company is broadly diversified geographically and in FY25, the company shipped c.13,600 cars with a geographical mix consisting of EMEA 46%, Americas 29% and Asia-Pacific 25%. The company is meticulous in its allocation of cars, with factors such as scarcity, end market demand, existing customer locations, and residual values all playing a part. Shipments have grown at c.6.5% p.a. since 2016 but depending on the timing of certain model launches, this number can fluctuate on a yearly basis. The company also carefully considers the price for each vehicle brought to the market, and in assessing the evolution of the average selling price (ASP) across its range, we estimate the price has risen at c.6% p.a. since 2016. As we have previously written, pricing power remains a key measure of business quality.

The impressive financials are a testament to the strength of the Ferrari brand and the pricing power that comes with it. Since its listing in 2016, the company has delivered a sales CAGR of c.10% p.a., while also growing EBITDA and EPS at c.14% p.a. and c.17% p.a., respectively. From a capital allocation perspective, approximately 50% of the free cash has been spent on capex and the balance returned to shareholders via dividends or buybacks.

We purchased the position following its 1Q26 results, where Ferrari delivered organic growth of 6% and 40 bps expansion in its EBIT margin (to 30.9%). Along with all luxury brands, the shares had de-rated meaningfully when we acquired the shares in May. We bought the position when Ferrari was trading at 28x next-twelve-month earnings. Despite the subsequent adverse publicity around the Ferrari Luce electric vehicle release, the shares have since rerated to 33x next-twelve-month earnings, which is 10% below the 10-year average of 37x.

Meta Platforms (Meta-US) – The company operates a family of social media applications: Facebook, Instagram, WhatsApp, Messenger, and more recently Threads. Advertising accounts for approximately 98% of the company's total revenue, making it one of the world's leading advertising platforms. As of December 2025, Meta's Family of Apps averaged 3.6 billion daily active people - nearly half the world's population engages with a Meta product on any given day. This is a company with an exceptionally strong network effect.

Throughout its history, Meta has delivered consistently strong financial results. And the core advertising business continues to compound at a rate that is remarkable for a company of its size, underpinned by engagement improvements from AI-powered content ranking, and the Advantage+ automated ad system. Full-year 2025 revenue was US$201 billion, a 22% increase over 2024, which in turn grew 22% over 2023. Operating income for 2025 was US$83 billion, and operating leverage has seen ongoing margin expansion, with the 2025 operating margin at 41%. Financial momentum has carried into 2026 with ad impression volumes, and average price per ad, both continuing to rise, driving a 33% year-over-year revenue increase in the first quarter.

Meta is investing aggressively in AI infrastructure, which has weighed on free cash flow and sentiment recently. It has also contributed to stock price volatility. Yet, despite considerable capital expenditure, the balance sheet remains strong. At year-end, the company had very limited debt (with US$82 billion in cash and marketable securities / gross debt of US$85bn). We have seen periods of heavy capital expenditure weigh on Meta's share price previously. We have also seen these periods pass, and the benefits of prior capital expenditure result in subsequent growth and free cash flow generation.

As at writing, Meta's forward P/E is currently c.18.0x, a 20% discount to its ten-year historical average. The valuation does not appear stretched relative to the business's competitive advantages and growth profile.

Portfolio removals

Sika AG (Sika-SW) – We exited this small position to make way for better opportunities in the portfolio. Whilst Sika is an excellent company at a very fair price, near-term growth prospects look sluggish. We also have exposure to US construction in the portfolio through Allegion. There is no loss of competitive advantage, and the company remains on the A-list and a potential portfolio inclusion in the future.

Zoetis (ZTS-US) – please refer above to detractors for the quarter.

Securities movements for the quarter

Bought in	Meta	Ferrari
Sold out	Sika	zoetis
Increased holding	CME Group VISA	
Decreased holding	adyen jack henry	MARSH

Claremont Global Fund
(Hedged)
Own the world's best businesses

Q2 2026 Report
CGHE:ASX

How to invest

Available via ASX

Available via platform

Available via application form

ClaremontGlobal.com.au

Research ratings

Invest now

Fund details

Strategy AUM	A$590M
Structure	Retail unit trust & Active ETF
ASX Ticker	CGHE
Max. single stock weight	10%
Max. cash weight	10%
Management fee	1.25%
Performance fee	Nil
APIR	ETL0391AU
ARSN	166 708 407
ISIN	AU60ETL03919
Responsible entity	Equity Trustees
Administrator & Custodian	Apex
Market maker	Nine Mile
Currency exposure	Hedged
Fund inception	18th February 2014
Buy/sell spread	0.10% / 0.10%

Contact us

E: contact@claremontglobal.com.au
T: 1300 684 537
W: claremontglobal.com.au

Clinton Boltman Investment Associate

riaa Responsible Investment Association Australasia